Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET Imaging in Cancer Patients
NCT03142204Phase 1Unknown
- Sponsor
- CellSight Technologies
- Start
- May 2017
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]fluoro-arabinofuranosyl guanine in cancer, sponsored by CellSight Technologies. Primary endpoints: Biodistribution of [18F]F-AraG pre-immunotherapy and Biodistribution of [18F]F-AraG post start of immunotherapy. Status: unknown.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03142204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142204.